XSTO
IVACC
Market cap38mUSD
Jun 05, Last price
1.08SEK
1D
2.86%
1Q
8.00%
IPO
-84.44%
Name
Intervacc AB
Chart & Performance
Profile
Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 11,787 47.06% | 8,015 -17.23% | 9,684 84.77% | |||||||
Cost of revenue | 15,314 | 39,366 | 47,746 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (3,527) | (31,351) | (38,062) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 11,388 | 3 | ||||||||
Tax Rate | ||||||||||
NOPAT | (3,527) | (42,739) | (38,065) | |||||||
Net income | (75,515) -26.58% | (102,852) 60.31% | (64,158) 118.41% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 103,506 | 6,120 | ||||||||
BB yield | -26.82% | -0.41% | ||||||||
Debt | ||||||||||
Debt current | 39 | 139 | ||||||||
Long-term debt | 142 | 183 | ||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 106 | |||||||||
Net debt | (34,404) | (88,160) | 126,955 | |||||||
Cash flow | ||||||||||
Cash from operating activities | (53,195) | (45,834) | (69,790) | |||||||
CAPEX | (706) | (56) | (6,132) | |||||||
Cash from investing activities | (706) | (2,107) | (6,132) | |||||||
Cash from financing activities | (36) | 90,583 | 5,909 | |||||||
FCF | (3,191) | (29,275) | (51,669) | |||||||
Balance | ||||||||||
Cash | 34,404 | 88,341 | 45,699 | |||||||
Long term investments | (172,332) | |||||||||
Excess cash | 33,815 | 87,940 | ||||||||
Stockholders' equity | 15,147 | 151,473 | (42,888) | |||||||
Invested Capital | 147,288 | 150,172 | 293,369 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 88,280 | 60,963 | 57,908 | |||||||
Price | 1.17 -81.52% | 6.33 -75.65% | 26.00 -51.13% | |||||||
Market cap | 103,288 -73.23% | 385,896 -74.37% | 1,505,609 -51.00% | |||||||
EV | 68,884 | 297,736 | 1,632,564 | |||||||
EBITDA | (3,527) | (6,752) | (17,204) | |||||||
EV/EBITDA | ||||||||||
Interest | 133 | 125 | ||||||||
Interest/NOPBT |